ArticleBiosensors2026
Microfluidic Light-Scattering Imaging Coupled with Deep Learning for Label-Free Single-Cell Classification of Lymphoma Cells.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Accurate classification of lymphoma cell subtypes is essential for disease diagnosis and therapeutic decision-making, yet conventional approaches often rely on fluorescence labeling, labor-intensive sample preparation, and specialized instrumentation, limiting their applicability for rapid, label-free single-cell analysis. Here, we present an AI-assisted microfluidic light-scattering imaging platform for label-free classification of lymphoma cells. The platform integrates hydrodynamic focusing within a microfluidic chip, continuous acquisition of two-dimensional (2D) light-scattering patterns, automated image preprocessing, and transfer learning based on a pretrained ResNet50 network for intelligent optical feature extraction and classification. Human B lymphoma (Daudi) and T lymphoblastic lymphoma (SUP-T1) cells were used to evaluate the proposed framework. The optical imaging system was first validated using standard microspheres, demonstrating reliable acquisition of light-scattering patterns under continuous-flow conditions. A dataset comprising 800 single-cell scattering patterns was subsequently established and evaluated using stratified five-fold cross-validation. The proposed framework achieved an average classification accuracy of 94.75% with an average area under the receiver operating characteristic (ROC) curve of 0.986. By integrating microfluidic optical biosensing with deep learning, this work enables automated interpretation of intrinsic optical scattering signatures and provides a promising AI-enabled strategy for rapid, label-free lymphoma screening and intelligent healthcare applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.